This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
AmerisourceBergen (ABC) Q4 Earnings & Revenues Beat Estimates
by Zacks Equity Research
AmerisourceBergen's (ABC) Q4 earnings benefit from higher revenues, segmental growth and strong fiscal 2020 outlook.
Insulet (PODD) Beats on Q3 Earnings, Ups '19 Revenue View
by Zacks Equity Research
Insulet's (PODD) year-over-year improvement in Q3 revenues on the solid uptake of Omnipod system both in the United States and across international markets looks promising.
OPKO Health (OPK) Q3 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
OPKO Health (OPK) third-quarter results benefit from higher Product revenues and RAYALDEE prescription growth.
CVS Health (CVS) Beats on Q3 Earnings, Raises '19 EPS Guidance
by Zacks Equity Research
CVS Health's (CVS) strong year-over-year growth in the top line is aided by a robust performance at the Pharmacy Services segment.
Phibro's (PAHC) Q1 Earnings & Revenues Fall Y/Y, Margins Down
by Zacks Equity Research
Phibro (PAHC) exhibits a dismal first-quarter performance on a decline in revenues at core business segments.
HMS Holdings (HMSY) Q3 Earnings Top Estimates, Revenues Miss
by Zacks Equity Research
HMS Holdings' (HMSY) Q3 earnings benefit from higher revenues at Analytical Services unit and strong 2019 outlook.
Avanos (AVNS) Earnings and Revenues Miss Estimates in Q3
by Zacks Equity Research
Avanos (AVNS) third-quarter results benefit from higher revenues and strong segmental performance.
NUVA vs. RMD: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
NUVA vs. RMD: Which Stock Is the Better Value Option?
Inogen's (INGN) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Softness in domestic and international business-to-business revenues impact Inogen's (INGN) Q3 results.
STERIS' (STE) Q2 Earnings Surpass Estimates, FY20 View Up
by Zacks Equity Research
STERIS (STE) witnesses solid revenue growth across each of its operating segments in the second quarter of fiscal 2020.
Zimmer Biomet (ZBH) Q3 Earnings Top, Operating Margin Falls
by Zacks Equity Research
Zimmer Biomet (ZBH) gains from strong sales growth across all geographies and most operating segments in Q3.
Hill-Rom's (HRC) Q4 Earnings Beat on Strong Global Sales
by Zacks Equity Research
Internationally, Asia Pacific, Latin America and EMEA registers strong revenue growth for Hill-Rom (HRC).
Allscripts (MDRX) Q3 Earnings Beat Estimates, Improve Y/Y
by Zacks Equity Research
Allscripts (MDRX) third-quarter results gain from growth in bookings and solid segmental performance. Contraction in both gross and operating margins remains a woe.
Luminex (LMNX) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Luminex's (LMNX) Q3 earnings benefit from higher revenues and solid performance across System Sales, Consumable Sales and Service Revenues. However, gross margin contraction remains a woe.
Myriad Genetics (MYGN) Lags Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Myriad Genetics (MYGN) observes a decline in Hereditary Cancer, GeneSight, Vectra as well as Other testing revenues in Q1.
Henry Schein (HSIC) Q3 Earnings Top Estimates, Revenues Lag
by Zacks Equity Research
Henry Schein (HSIC) registers solid performance across its key operating businesses in Q3.
Becton, Dickinson (BDX) Beats on Q4 Earnings and Revenues
by Zacks Equity Research
Becton, Dickinson (BDX) gains from solid segmental contributions in Q4.
Tandem Diabetes (TNDM) Q3 Loss Narrows Y/Y, Sales Improve
by Zacks Equity Research
Tandem Diabetes (TNDM) exhibits a robust performance in the third quarter of 2019, fueled by strong domestic demand.
Intersect ENT (XENT) Reports Q3 Loss, Revenues Meet Estimates
by Zacks Equity Research
Intersect ENT (XENT) exhibits a dismal performance in the third quarter of 2019.
Haemonetics (HAE) Beats on Q2 Earnings, Raises '20 EPS View
by Zacks Equity Research
Haemonetics (HAE) delivers robust fiscal second-quarter revenues, fueled by strong performances in Plasma and Hospital segments.
Surmodics (SRDX) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Surmodics (SRDX) continues to gain from core Medical Devices unit, which saw significant contribution from the SurVeil deal with Abbott in Q4.
Bio-Rad (Bio) Q3 Earnings Beat Estimates on All-Line Growth
by Zacks Equity Research
Growing strength in many of Bio-Rad's (Bio) key product lines across major geographic regions buoys investors' optimism on the stock.
Syneos Health (SYNH) Tops Q3 Earnings Estimates, Ups EPS View
by Zacks Equity Research
Syneos Health (SYNH) exhibits robust topline performance in the third quarter, backed by strong segmental growth.
Integer Holdings (ITGR) Beats on Q3 Earnings, Revenues Miss
by Zacks Equity Research
Integer Holdings' (ITGR) Q3 earnings benefit from higher revenues and strong 2019 outlook.
Bruker (BRKR) Beats Q3 Earnings Estimates, Ups EPS Guidance
by Zacks Equity Research
Bruker (BRKR) delivers robust third-quarter revenue growth, backed by strong segmental performances.